# Performance Certificate 2022



Member of UK NEQAS consortium

### **GenQA Participant laboratory/centre:**

### **Clinical Genetics, Nijmegen**

Radboud University Nijmegen Medical Centre, Dept Genetics - 848 Geert Grooteplein-Zuid 10 P.O. box 9101 Nijmegen 6525 GA Netherlands

This certificate confirms participation and performance for the above laboratory/centre on 01 September 2023 for the following 2022 GenQA EQA programmes:

## EQA

2022 BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline
2022 BRCA testing for ovarian and prostate cancer - somatic
2022 Chromosome Breakage syndromes
2022 Chronic Lymphocytic Leukaemia (CLL)
2022 Disorders of Sex Development (DSD)
2022 Eye Disorders
2022 Familial Colorectal Cancer and Polyposis

2022 Familial endocrine tumour predisposition disorders

## **Performance status**

Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory

It is expected that satisfactory performance will be attained. Thank you for your participation.

**Oxford Office** 

lans

Professor Sandi Deans GenQA Director

## Inspiring Genomic Excellence

info@genqa.org • www.genqa.org • +44 (0)131 242 6898

#### **Edinburgh Office**

Laboratory Medicine, NHS Lothian NINE, Edinburgh BioQuarter Little France Road Edinburgh EH16 4UX United Kingdom Women's Centre, John Radcliffe Hospital Oxford University Hospitals NHS Foundation Trust Headley Way Oxford OX3 9DU United Kingdom

CONFIDENTIAL Copyright © GenQA GenQA is operated under the legal entity of OUH NHS Foundation Trust and is provided from two sites. GenQA is a UKAS accredited proficiency testing provider.

Page 1 of 2

# Performance Certificate 2022



Member of UK NEQAS consortium

### **GenQA Participant laboratory/centre:**

### **Clinical Genetics, Nijmegen**

Radboud University Nijmegen Medical Centre, Dept Genetics - 848 Geert Grooteplein-Zuid 10 P.O. box 9101 Nijmegen 6525 GA Netherlands

This certificate confirms participation and performance for the above laboratory/centre on 01 September 2023 for the following 2022 GenQA EQA programmes:

## EQA

2022 Infertility

2022 Maternal cell contamination (MCC) & sexing

2022 Myeloid disorders

2022 Pathogenicity of germline postnatal copy number variant (CNV)

2022 Pathogenicity of germline sequence variants (Classification & Interpretation)

2022 Pregnancy loss (G-banding and molecular methods)

### **Performance status**

Satisfactory Satisfactory Satisfactory Not applicable (pilot EQA) <sup>n</sup> Satisfactory

Satisfactory

It is expected that satisfactory performance will be attained. Thank you for your participation.

**Oxford Office** 

lans

Professor Sandi Deans GenQA Director

## Inspiring Genomic Excellence

info@genqa.org • www.genqa.org • +44 (0)131 242 6898

#### **Edinburgh Office**

Laboratory Medicine, NHS Lothian NINE, Edinburgh BioQuarter Little France Road Edinburgh EH16 4UX United Kingdom Women's Centre, John Radcliffe Hospital Oxford University Hospitals NHS Foundation Trust Headley Way Oxford OX3 9DU United Kingdom

CONFIDENTIAL Copyright © GenQA GenQA is operated under the legal entity of OUH NHS Foundation Trust and is provided from two sites. GenQA is a UKAS accredited proficiency testing provider.

Page 2 of 2